BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O’Connor A, Gisbert JP, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection 2010. Helicobacter. 2010;15 Suppl 1:46-52. [PMID: 21054653 DOI: 10.1111/j.1523-5378.2010.00774.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Ozturk A. Periodontal Treatment Is Associated With Improvement in Gastric Helicobacter pylori Eradication: An Updated Meta-analysis of Clinical Trials. Int Dent J 2021;71:188-96. [PMID: 34024329 DOI: 10.1111/idj.12616] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Abadi AT, Taghvaei T, Ghasemzadeh A, Mobarez AM. High frequency of A2143G mutation in clarithromycin-resistant Helicobacter pylori isolates recovered from dyspeptic patients in Iran. Saudi J Gastroenterol. 2011;17:396-399. [PMID: 22064338 DOI: 10.4103/1319-3767.87181] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
3 Celik MM, Duran N. An experimental in-vitro study to evaluate the anti-helicobacter activity of Glycyrrhetinic acid. Revista Romana de Medicina de Laborator 2019;27:63-71. [DOI: 10.2478/rrlm-2019-0003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Wallace MC, Rankin J, Forbes GM. Acute gastrointestinal bleeding after percutaneous coronary intervention. Expert Rev Gastroenterol Hepatol. 2012;6:211-221. [PMID: 22375526 DOI: 10.1586/egh.11.104] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
5 Peretz A, Paritsky M, Dinisman-Zavulunov E, Pastukh N, Glyatman T, On A. Susceptibility of Helicobacter pylori to Levofloxacin and Rifampicin in Israel. Microb Drug Resist 2015;21:448-51. [PMID: 25793253 DOI: 10.1089/mdr.2014.0250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Talebi Bezmin Abadi A. Vaccine against Helicobacter pylori: Inevitable approach. World J Gastroenterol 2016; 22(11): 3150-3157 [PMID: 27003991 DOI: 10.3748/wjg.v22.i11.3150] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
7 Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51-69.e14. [PMID: 27102658 DOI: 10.1053/j.gastro.2016.04.006] [Cited by in Crossref: 362] [Cited by in F6Publishing: 311] [Article Influence: 60.3] [Reference Citation Analysis]
8 Alkim H, Iscan M, Oz F. Effectiveness of ranitidine bismuth citrate and proton pump inhibitor based triple therapies of Helicobacter pylori in Turkey. Libyan J Med. 2011;6. [PMID: 21912572 DOI: 10.3402/ljm.v6i0.8412] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
9 Abadi AT, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol 2011;49:987-93. [PMID: 22203563 DOI: 10.1007/s12275-011-1170-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
10 Wang AY, Peura DA. The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. Gastrointest Endosc Clin N Am. 2011;21:613-635. [PMID: 21944414 DOI: 10.1016/j.giec.2011.07.011] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
11 Peretz A, Paritsky M, Nasser O, Brodsky D, Glyatman T, Segal S, On A. Resistance of Helicobacter pylori to tetracycline, amoxicillin, clarithromycin and metronidazole in Israeli children and adults. J Antibiot 2014;67:555-7. [DOI: 10.1038/ja.2014.38] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
12 Liu Z, Ren W, Guo J, Zhao Y, Sun S, Li Y, Liu Z. Preliminary opinion on assessment categories of stomach ultrasound report and data system (Su-RADS). Gastric Cancer 2018;21:879-88. [PMID: 29372460 DOI: 10.1007/s10120-018-0798-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
13 Shahbazi S, Vahdat Shariatpanahi Z. Comparison between  daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled  trial. Indian J Gastroenterol 2018;37:550-4. [DOI: 10.1007/s12664-018-0916-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
14 Lim HC, Lee YJ, An B, Lee SW, Lee YC, Moon BS. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori. Helicobacter. 2014;19:455-461. [PMID: 25231089 DOI: 10.1111/hel.12147] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
15 Gisbert JP, Calvet X, Ferrándiz J, Mascort J, Alonso-Coello P, Marzo M; Sociedad Española de Medicina de Familia y Comunitaria. [Clinical practice guideline on the management of patients with dyspepsia. Update 2012]. Gastroenterol Hepatol 2012;35:725.e1-38. [PMID: 23186826 DOI: 10.1016/j.gastrohep.2012.05.002] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
16 Marzano IM, Franco MS, Silva PP, Augusti R, Santos GC, Fernandes NG, Bucciarelli-Rodriguez M, Chartone-Souza E, Pereira-Maia EC. Crystal structure, antibacterial and cytotoxic activities of a new complex of bismuth(III) with sulfapyridine. Molecules 2013;18:1464-76. [PMID: 23348999 DOI: 10.3390/molecules18021464] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
17 Talebi Bezmin Abadi A, Ghasemzadeh A, Taghvaei T, Mobarez AM. Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran. Intern Emerg Med. 2012;7:447-452. [PMID: 21437583 DOI: 10.1007/s11739-011-0563-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
18 Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011;34:1255-1268. [PMID: 22017749 DOI: 10.1111/j.1365-2036.2011.04887.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 7.2] [Reference Citation Analysis]
19 Hajji R, Hajji S, Ben Ahmed A, Nasri M, Hlel F. Synthesis, physical characterization, thermal studies, biological activities and DFT computations on the molecular structure and vibrational spectra of [C7H12N2]2Bi2Br10·4H2O compound. Journal of Solid State Chemistry 2020;288:121402. [DOI: 10.1016/j.jssc.2020.121402] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:209-221. [PMID: 22129228 DOI: 10.1111/j.1365-2036.2011.04937.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 113] [Article Influence: 10.5] [Reference Citation Analysis]
21 Gisbert JP, Pérez-Aisa A, Bermejo F, Castro-Fernández M, Almela P, Barrio J, Cosme A, Modolell I, Bory F, Fernández-Bermejo M. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. J Clin Gastroenterol. 2013;47:130-135. [PMID: 22647827 DOI: 10.1097/mcg.0b013e318254ebdd] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
22 Suk KT, Baik SK, Kim HS, Park SM, Paeng KJ, Uh Y, Jang IH, Cho MY, Choi EH, Kim MJ. Antibacterial effects of the urushiol component in the sap of the lacquer tree (Rhus verniciflua Stokes) on Helicobacter pylori. Helicobacter. 2011;16:434-443. [PMID: 22059394 DOI: 10.1111/j.1523-5378.2011.00864.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
23 Gisbert JP, Calvet X, Ferrándiz J, Mascort J, Alonso-Coello P, Marzo M; Asociación Española de Gastroenterología., Sociedad Española de Medicina de Familia y Comunitaria., Centro Cochrane Iberoamericano. [Clinical practice guideline on the management of patients with dyspepsia. Update 2012]. Aten Primaria 2012;44:727.e1-727.e38. [PMID: 23036729 DOI: 10.1016/j.aprim.2012.05.003] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
24 Gisbert JP. Helicobacter pylori eradication: A new, single-capsule bismuth-containing quadruple therapy. Nat Rev Gastroenterol Hepatol. 2011;8:307-309. [PMID: 21643037 DOI: 10.1038/nrgastro.2011.84] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
25 Polat Z, Kadayifci A, Kantarcioglu M, Ozcan A, Emer O, Uygun A. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori. Eur J Intern Med. 2012;23:165-168. [PMID: 22284248 DOI: 10.1016/j.ejim.2011.02.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
26 Rasheed F, Campbell BJ, Alfizah H, Varro A, Zahra R, Yamaoka Y, Pritchard DM. Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance. Helicobacter. 2014;19:387-399. [PMID: 24827414 DOI: 10.1111/hel.12142] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
27 Ghasemian A, Fattahi A, Shokouhi Mostafavi SK, Almarzoqi AH, Memariani M, Ben Braiek O, Yassine HM, Mostafavi NSS, Ahmed MM, Mirforughi SA. Herbal medicine as an auspicious therapeutic approach for the eradication of Helicobacter pylori infection: A concise review. J Cell Physiol. 2019;234:16847-16860. [PMID: 30847906 DOI: 10.1002/jcp.28363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
28 Pan-in P, Tachapruetinun A, Chaichanawongsaroj N, Banlunara W, Suksamrarn S, Wanichwecharungruang S. Combating Helicobacter pylori infections with mucoadhesive nanoparticles loaded with Garcinia mangostana extract. Nanomedicine 2014;9:457-68. [DOI: 10.2217/nnm.13.30] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
29 Yilmaz B, Koseoglu H, Coskun Y, Deveci M, Kekilli M. Comparison between different first-line therapy protocols in eradicating Helicobacter pylori in a region with high clarithromycin resistance. Prz Gastroenterol 2018;13:150-6. [PMID: 30002775 DOI: 10.5114/pg.2018.72732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Lee ST, Lee DH, Lim JH, Kim N, Park YS, Shin CM, Jo HJ, Song IS. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection. Gut Liver. 2015;9:478-485. [PMID: 25071068 DOI: 10.5009/gnl14020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
31 Jones N, Chiba N, Fallone C, Thompson A, Hunt R, Jacobson K, Goodman K; Canadian Helicobacter Study Group Participants. Helicobacter pylori in First Nations and recent immigrant populations in Canada. Can J Gastroenterol 2012;26:97-103. [PMID: 22312609 DOI: 10.1155/2012/174529] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
32 Mehling H, Busjahn A. Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans. Nutrients 2013;5:3062-73. [PMID: 23917169 DOI: 10.3390/nu5083062] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
33 Ertem D. Clinical Practice: Helicobacter pylori infection in childhood. Eur J Pediatr 2013;172:1427-34. [DOI: 10.1007/s00431-012-1823-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
34 Saracino IM, Zaccaro C, Re GL, Vaira D, Holton J. The Effects of Two Novel Copper-Based Formulations on Helicobacter pylori. Antibiotics (Basel) 2013;2:265-73. [PMID: 27029303 DOI: 10.3390/antibiotics2020265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Kobayashi J, Kawakubo M, Fujii C, Arisaka N, Miyashita M, Sato Y, Komura H, Matoba H, Nakayama J. Cholestenone functions as an antibiotic against Helicobacter pylori by inhibiting biosynthesis of the cell wall component CGL. Proc Natl Acad Sci U S A 2021;118:e2016469118. [PMID: 33853940 DOI: 10.1073/pnas.2016469118] [Reference Citation Analysis]
36 Basarab GS, Hill P, Eyermann CJ, Gowravaram M, Käck H, Osimoni E. Design of inhibitors of Helicobacter pylori glutamate racemase as selective antibacterial agents: Incorporation of imidazoles onto a core pyrazolopyrimidinedione scaffold to improve bioavailabilty. Bioorganic & Medicinal Chemistry Letters 2012;22:5600-7. [DOI: 10.1016/j.bmcl.2012.07.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
37 Karczewska E, Klesiewicz K, Skiba I, Wojtas-bonior I, Sito E, Czajecki K, Zwolińska-wcisło M, Budak A. Variability in Prevalence of Helicobacter pylori Strains Resistant to Clarithromycin and Levofloxacin in Southern Poland. Gastroenterology Research and Practice 2012;2012:1-7. [DOI: 10.1155/2012/418010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
38 Wu TS, Hu HM, Kuo FC, Kuo CH. Eradication of Helicobacter pylori infection. Kaohsiung J Med Sci. 2014;30:167-172. [PMID: 24656156 DOI: 10.1016/j.kjms.2013.11.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]